Clinical Data Vilazodone obtains US patent
Clinical Data said that the issued patent, which will expire in June 2022, covers Vilazodone HC1 in Form IV, its process of preparation and method of treatment therewith.
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.